How to Bill VenaSeal, Varithena and ClariVein Correctly

Billing VenaSeal, Varithena and ClariVein nonthermal vein treatments

Accurate nonthermal vein ablation billing depends on three things: using the right CPT codes for each device, checking the coverage policy of the specific MAC or payer, and keeping documentation that meets that policy. The codes are 36482/36483 for VenaSeal, 36465/36466 for Varithena and 36473/36474 for ClariVein. Coverage varies by payer: several Medicare LCDs name cyanoacrylate and MOCA as covered, while UnitedHealthcare and Aetna treat MOCA as unproven.

Key Takeaways on Nonthermal Vein Ablation Billing

  • Bill VenaSeal with 36482 plus add-on 36483, and ClariVein with 36473 plus add-on 36474, reporting each add-on only once per extremity.
  • Bill Varithena with 36465 for a single truncal vein or 36466 for multiple truncal veins in the same leg, and do not bill the drug separately.
  • Novitas, First Coast, Palmetto and Wellpoint Federal LCDs name cyanoacrylate and MOCA as covered, while the Noridian, WPS and CGS LCDs do not name these devices.
  • UnitedHealthcare and Aetna cover cyanoacrylate when criteria are met but treat mechanochemical ablation as unproven or experimental.
  • Documentation should include symptoms, the conservative therapy trial, duplex reflux and diameter findings, laterality, and a plan of care that names the device.
  • Issue a specific ABN before the service when you expect Original Medicare to deny it, and append GA when a valid ABN is on file.

This guide covers how to code VenaSeal (cyanoacrylate adhesive closure), Varithena (polidocanol injectable microfoam) and ClariVein (mechanochemical ablation, or MOCA). It also covers current Medicare and commercial coverage, documentation and the denials we see most often.

CPT Codes and Initial vs. Subsequent Vein Rules

VenaSeal: 36482 and 36483

CPT 36482 reports the first vein treated with a chemical adhesive such as cyanoacrylate, delivered by transcatheter from a site remote from the access point. Add-on code 36483 covers each subsequent vein in the same extremity that is treated through a separate access site. Medtronic’s superficial venous coding guide says all endovenous ablation codes are used once per extremity. Novitas billing article A55229 and Wellpoint Federal article A52870 both state that 36483 is reported once per extremity, however many additional veins are treated.

Bill 36483 only with 36482 on the same leg. First Coast’s medical review team has flagged hospital outpatient claims that listed a second-vein code such as 36483 without the matching first-vein code.

ClariVein: 36473 and 36474

Mechanochemical ablation is reported with 36473 for the first vein and add-on 36474 for subsequent veins in the same extremity through separate access sites. The descriptor for 36473 includes all imaging guidance and monitoring, so do not bill ultrasound guidance separately. Novitas A55229 limits 36474 to one unit per extremity, the same rule as the other subsequent-vein codes.

Varithena: 36465 and 36466

Varithena is a non-compounded foam sclerosant. Code it with 36465 for a single incompetent extremity truncal vein, such as the great or accessory saphenous vein, and with 36466 for multiple incompetent truncal veins in the same leg. These are not first-vein and add-on codes. 36466 replaces 36465 when more than one truncal vein is treated, and Wellpoint Federal A52870 allows it once per extremity. Boston Scientific’s 2025 coding guide notes that ultrasound guidance and monitoring are built into both descriptors. It also says that when ultrasound-guided foam is used on a truncal vein, you should report 36465 or 36466 rather than 36470 or 36471.

Drug, supply and imaging considerations

  • No separate drug code for Varithena. Novitas A55229 says the sclerosant is included in the procedure code and is not reported separately. Neither the Varithena coding guide nor its reimbursement page lists a HCPCS drug code.
  • Office supplies are included. In the office setting, Wellpoint Federal and Novitas both bundle supplies and equipment for 36465, 36466, 36473, 36482 and 36483. That means the VenaSeal kit and the ClariVein catheter are not billed separately. Novitas also bundles the compression dressing.
  • Use laterality modifiers. Wellpoint Federal returns claims without RT, LT or 50 as unprocessable. ASCs bill RT and LT on separate lines and do not use modifier 50.
  • Do not use 37241. First Coast and Novitas both state that 37241 is incorrect coding for vein ablation in chronic venous insufficiency.

Medicare Coverage: It Depends on Your MAC

There is no national coverage determination for these treatments, so each Medicare Administrative Contractor (MAC) sets coverage in its own Local Coverage Determination (LCD). Years ago, several MACs treated cyanoacrylate closure and MOCA as unproven. The current LCDs we reviewed in November 2026 fall into two groups.

MACs that name cyanoacrylate and MOCA as covered

  • Novitas (L34924; JH and JL) and First Coast (L38720; JN) treat chemical adhesives and mechanochemical ablation as reasonable and necessary for incompetent saphenous veins in symptomatic CEAP C2 to C6 disease. Neither LCD names Varithena. Its coverage falls under their general foam sclerotherapy language.
  • Palmetto GBA (L39121; JJ and JM) covers cyanoacrylate and MOCA for incompetent great, small and anterior accessory saphenous veins. It does not list them for perforator veins. Varithena is not named.
  • Wellpoint Federal, formerly NGS (L33575; J6 and JK) says its coverage criteria are met for cyanoacrylate, MOCA and polidocanol endovenous microfoam as alternatives to standard ablation. It caps vein diameter at 12 mm for all three and requires a six-week conservative therapy trial.

MACs whose LCDs do not name these devices

  • Noridian (L34209; JE and JF) addresses only radiofrequency and laser ablation by name and requires a 3-month conservative therapy trial. However, its billing article A57706 lists 36465, 36466, 36473, 36474, 36482 and 36483 among the codes that support medical necessity.
  • WPS (L34536; J5 and J8) does not mention cyanoacrylate, MOCA or microfoam, and it requires 3 months of conservative care.
  • CGS (L34082; J15) does not name these devices either. It says sclerotherapy of the saphenous vein at its junction with the deep system is not covered, which is worth reviewing before you bill Varithena there.

Tip: Map each practice location to its MAC and LCD. Where the LCD does not name the device you plan to use, contact the MAC before you assume coverage.

Prior authorization is a separate requirement. Since July 2020, CMS has required it for vein ablation codes 36473 through 36483 in the hospital outpatient department. In 2026 it extended the requirement to 36473, 36475, 36478 and 36482 performed in ASCs in ten states, including California, Florida, Texas and New York.

Practices that bill across several MAC jurisdictions often run into trouble at this step. A team that specializes in vein and vascular medical billing services can map each location to its LCD and set up the right edits in your billing system.

Commercial Payer Patterns

  • UnitedHealthcare (commercial policy 2026T0447RR, effective January 1, 2026) considers cyanoacrylate medically necessary for truncal veins when criteria are met, but unproven for perforators. Mechanochemical ablation is unproven for venous reflux. Truncal veins must measure at least 3 mm with reflux of at least 500 ms.
  • Aetna (CPB 0050, reviewed August 2026) lists 36482 and 36483 and 36465 and 36466 as covered when criteria are met. It lists 36473 and 36474 as not covered because it considers MOCA experimental. Aetna requires a 3-month trial of conservative management with compression of 20 mmHg or more, junctional reflux of 500 ms or more on imaging from the past 6 months, and a saphenous diameter of at least 4.5 mm.
  • Cigna retired its varicose vein policy 0234 for dates of service on or after November 1, 2024, and moved review to eviCore. The retired policy treated ClariVein as experimental and covered cyanoacrylate. Boston Scientific reports that Cigna expanded Varithena coverage in late 2024. Confirm current criteria with eviCore.
  • Anthem (Elevance): Anthem’s April 2025 revision of CG-SURG-119 listed cyanoacrylate as not medically necessary. Six specialty societies asked Anthem to reverse that change in June 2025. Check the current version before you schedule VenaSeal for Anthem members.

Caution: Anthem’s and Cigna’s policies for these treatments have changed recently. Confirm the current guideline and prior authorization requirements before scheduling, not after the claim is denied.

TreatmentCPTCoverage notesDocumentation focus
VenaSeal (cyanoacrylate)36482; +36483 (once per extremity)Named as covered by Novitas, First Coast, Palmetto and Wellpoint Federal. Covered by UHC (truncal) and Aetna. Listed as not medically necessary in Anthem’s April 2025 guideline.Plan of care naming the adhesive, a complete operative note, duplex reflux and diameter, a vein no larger than 12 mm under Wellpoint Federal
Varithena (polidocanol microfoam)36465 (single truncal vein) or 36466 (multiple, same leg)Named by Wellpoint Federal. Other MACs cover it under general foam language. Covered by Aetna and UHC when criteria are met. Drug is not billed separately.Truncal vein identified, laterality, duplex findings, confirmation that an FDA-approved non-compounded foam was used
ClariVein (MOCA)36473; +36474 (once per extremity)Named as covered by Novitas, First Coast, Palmetto and Wellpoint Federal. Unproven or experimental under UHC and Aetna.Plan of care naming MOCA, an operative note, a signed ABN or patient financial agreement where the payer excludes it

Documentation That Holds Up

Novitas and First Coast expect a plan of care covering a 90-day episode. It should include the history and physical, CEAP class, revised VCSS, a formal duplex scan with exam dates, and the specific treatment planned. If cyanoacrylate or MOCA is planned, the plan must say so, and a complete operative note must support the claim. For C2 or C3 patients with a VCSS below 6, document 2 to 4 weeks of conservative care with compression of at least 20 to 30 mmHg.

Across the policies we reviewed, the core elements are the same:

  • Symptoms that limit daily activities, such as pain, edema, bleeding, phlebitis, dermatitis or ulceration
  • The type and length of the conservative therapy trial and its outcome, plus the reason if the patient cannot tolerate compression
  • Duplex findings: the vein treated, its diameter, reflux of at least 500 ms, and whether there is deep venous obstruction or DVT
  • Laterality and the specific veins treated, which should match the codes and modifiers on the claim
  • Justification for serial sessions on the same leg. Novitas expects documentation of why they could not be done on a single day.

When to Use an ABN

For Original Medicare patients, issue an Advance Beneficiary Notice (CMS-R-131) when you expect Medicare to deny a service as not reasonable and necessary. One example is a patient who does not meet the LCD’s conservative therapy or reflux criteria. Another is a service in a jurisdiction whose LCD does not address the device. The ABN must be delivered early enough for the patient to decide, and it must list the specific service. First Coast states that routine ABNs and generic statements that payment is uncertain are not acceptable.

Append modifier GA when a valid ABN is on file. Use GZ when you expect a denial and no ABN was signed, and know that the practice then carries the liability. ABNs do not apply to commercial or Medicare Advantage plans. For those patients, use the payer’s own process or a patient financial agreement.

Common Denial Reasons

  1. The payer’s policy classifies the device as experimental or unproven, as UHC and Aetna do for MOCA
  2. Prior authorization was not obtained, or the service was performed outside the approved date range
  3. The conservative therapy trial was missing or too short for that payer (anywhere from 2 to 4 weeks up to 3 months)
  4. Duplex results do not show qualifying reflux or vein diameter, or the imaging is too old
  5. The add-on code was billed without its primary code, or more than one unit was billed per extremity
  6. Laterality modifiers were missing, or the diagnosis code does not support medical necessity
  7. The service was billed for perforator veins, which several policies exclude for cyanoacrylate and foam

This article is general information only. Coverage changes often, so verify each patient’s benefits and the payer’s current policy before treatment.

Need Help Billing Nonthermal Vein Treatments?

If VenaSeal, Varithena or ClariVein claims are bringing in more denials than they should, ORCM can help with insurance billing for vein and vascular centers. Request a free vascular billing audit to find coding, authorization and documentation gaps before they cost you revenue.

Frequently Asked Questions

What CPT codes are used for VenaSeal?

VenaSeal is billed with 36482 for the first vein and add-on 36483 for subsequent veins in the same extremity treated through separate access sites. Novitas and Wellpoint Federal allow 36483 once per extremity, however many additional veins are treated.

Is Varithena billed with a separate drug code?

No. Varithena is reported with 36465 or 36466, and Novitas billing article A55229 states that the sclerosant is included in the procedure code and not reported separately.

Does Medicare cover ClariVein mechanochemical ablation?

It depends on the MAC. The Novitas, First Coast, Palmetto and Wellpoint Federal LCDs name MOCA as covered when criteria are met, while the Noridian, WPS and CGS LCDs do not name it, so contact those MACs before you assume coverage.

Do commercial payers cover mechanochemical ablation?

Coverage is limited. UnitedHealthcare’s commercial policy considers MOCA unproven for venous reflux, and Aetna CPB 0050 lists 36473 and 36474 as not covered because it considers MOCA experimental.

When should a vein practice use an ABN?

Issue an ABN to an Original Medicare patient before the service when you expect Medicare to deny it as not reasonable and necessary, and list the specific service. Append modifier GA when a valid ABN is on file, and do not use routine or blanket ABNs.

In this guide
Get in touch